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Abstract.  The implantation  of bone morphogenetic 
protein (BMP) into muscular tissues induces ectopic 
bone formation at the site of implantation.  To inves- 
tigate the mechanism underlying this process, we ex- 
amined whether recombinant bone morphogenetic 
protein-2 (BMP-2) converts the differentiation pathway 
of the clonal myoblastic cell line,  C2C12, into that of 
osteoblast lineage.  Incubating the cells with 300 ng/ml 
of BMP-2 for 6 d almost completely inhibited the for- 
mation of the multinucleated myotubes expressing 
troponin T  and myosin heavy chain,  and induced the 
appearance of numerous alkaline phosphatase 
(ALP)-positive cells. BMP-2 dose dependently in- 
duced ALP activity, parathyroid hormone (PTH)- 
dependent 3',5'-cAMP production,  and osteocalcin 
production at concentrations above 100 ng/ml.  The 
concentration of BMP-2 required to induce these os- 
teoblastic phenotypes was the same as that required to 
almost completely inhibit myotube formation.  Incubat- 
ing primary muscle cells with 300 ng/ml of BMP-2 
for 6 d also inhibited myotube formation,  whereas in- 
duced ALP activity and osteocalcin production.  Incu- 
bation with 300 ng/ml of BMP-2 suppressed the ex- 
pression of mRNA for muscle creatine kinase within 
6 h,  whereas it induced mRNA expression for ALP, 
PTH/PTH-related protein (PTHrP) receptors, and os- 
teocalcin within 24--48  h.  BMP-2 completely inhibited 
the expression of myogenin mRNA by day 3.  By day 
3, BMP-2 also inhibited the expression of MyoD 
mRNA, but it was transiently  stimulated  12 h after ex- 
posure to BMP-2. Expression of Id-1 mRNA was 
greatly stimulated by BMP-2. When C2C12 cells 
pretreated with BMP-2 for 6 d were transferred to a 
colony assay system in the absence of BMP-2, more 
than  84 % of the colonies generated became troponin 
T-positive and ALP activity disappeared.  TGF-/31 also 
inhibited myotube formation in C2C12 cells, and sup- 
pressed the expression of myogenin and MyoD 
mRNAs without inducing that of Id-1 mRNA.  How- 
ever,  no osteoblastic phenotype was induced by TGF- 
/31 in C2C12 cells.  TGF-/31 potentiated the inhibitory 
effect of BMP-2 on myotube formation,  whereas TGF- 
/31 reduced ALP activity and osteocalcin production 
induced by BMP-2 in C2C12 cells. These results indi- 
cate that BMP-2 specifically converts the differentia- 
tion pathway of C2C12 myoblasts into that of osteo- 
blast lineage cells, but that the conversion is not 
heritable. 
S 
EVERAL lines  of evidence  indicate  that  osteoblasts, 
chondrocytes,  myocytes,  and  adipocytes are  all  de- 
rived from a common progenitor cell called undifferen- 
tiated mesenchymal cells (Taylor and Jones, 1979; Grigori- 
adis et al., 1988, 1990; Yamaguchi and Kahn,  1991). During 
the process of their differentiation,  progenitor cells acquire 
specific phenotypes depending  upon the differentiated  cell 
types under the control of respective regulatory factors (for 
reviews see Rodan and Rodan, 1984; Owen, 1988; Wlodar- 
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ski,  1990). The differentiation process of osteoblasts can be 
divided into at least two stages.  One is the commitment of 
undifferentiated mesenchymal  cells into osteoblast progeni- 
tors. The other is the maturation  of osteoblast progenitors 
into osteoblasts  which  express  the various phenotypes of 
bone-forming ceils; production of a large amount of extracel- 
lular matrix proteins including type I collagen and osteocal- 
cin,  high  levels  of alkaline  phosphatase  (ALP) ~ activity, 
1. Abbreviations  used in this paper:  ALE alkaline phosphatase; BMP, bone 
morphogenetic protein; HLH, helix-loop-helix; MCK, muscle creatine ki- 
nase; MHC, myosin heavy chain; PTH, parathyroid hormone; "In T, tropo- 
nin T. 
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thyroid hormone  (PTH)  and  lc~,25-dihydroxyvitamin D3 
(for reviews see Rodan and Rodan, 1984; Wlodarski, 1990). 
The regulatory mechanism of  osteoblast differentiation  at the 
maturation stage has been extensively studied using several 
osteoblast-like cell lines isolated from bone and bone mar- 
row (McAllister et al.,  1971; Heremans et al.,  1978;  Ma- 
jeska et al., 1980; Sudo et al., 1983; Partridge et al., 1983; 
Benayahu  et al., 1989). However, the mechanism of  the com- 
mitment to osteoblast differentiation is not fully understood 
because of a limited number of suitable in vitro model sys- 
tems reflecting the commitment of osteoblast differentiation 
from non-osteogenic cells. 
The molecular mechanism of myogenic differentiation has 
been well characterized using in vitro systems (for reviews 
see Olson, 1990; Weintraub et al., 1991; Wright, 1992; Ed- 
mondson and Olson,  1993;  Weintraub,  1993).  The  gene 
cloning of the muscle-specific regulatory factors,  MyoD, 
myogenin, Myf-5 and MRF4/herculin/Myf-6 has contrib- 
uted significantly  to the understanding of muscle differentia- 
tion (Davis et al., 1987; Wright et al., 1989; Edmondson and 
Olson,  1989;  Braun et al.,  1989;  Rhodes and Konieczny, 
1989; Fujisawa-Sehara et al., 1990; Miner and Wold, 1990; 
Braun  et  al.,  1990).  When  the  cDNAs  of these  regula- 
tory proteins  are  introduced into  pluripotent fibroblastic 
C3HlffI'I/2 cells, they differentiate into mature muscle cells 
(Davis et al., 1987; Wright et al., 1989; Edmondson and O1- 
son, 1989; Braun et al., 1989; Rhodes and Konieczny, 1989; 
Fujisawa-Sehara et al., 1990; Miner and Wold, 1990; Braun 
et al., 1990). These myogenic factors are called MyoD fam- 
ily and they are nuclear phosphorylated proteins that contain 
a common basic helix-loop-helix (bHLH) motif (Tapscott et 
al., 1988). The basic region of  this motif  is required for bind- 
ing to a specific DNA sequence, CANNTG (E-box), which 
is present in the promoters and enhancers of various muscle- 
specific  genes  including  muscle  creatine  kinase  (MCK) 
(Murre  et al.,  1989a;  Lassar et al.,  1989;  Davis  et al., 
1990). In addition, other members of helix-loop-helix  (HLH) 
factors (E12/E47  and Id-1) play important roles in the pro- 
cess of binding to DNA as well as in the transcriptional acti- 
vation of the muscle specific genes. El2 and E47, two differ- 
entially spliced products of  the E2A gene, form heterodimers 
with MyoD family proteins,  and these complexes bind to 
E-box with much higher affinity than homodimers of myo- 
genic HLH factors (Murre et al.,  1989b;  Brennan and Ol- 
son, 1990). Another HLH protein, Id-1, is a negative regula- 
tor of myogenesis (Benezra et al., 1990). Id-1 lacks the basic 
region in the conserved motif  which is necessary for binding 
to E-box (Benezra et al., 1990). It forms heterodimers with 
E12/E47  and prevents MyoD from forming complexes with 
E12/E47 in myoblasts (Benezra et al.,  1990). 
When demineralized bone matrix is implanted into mus- 
cular tissues, it induces the new bone formation at the im- 
plantation sites (Urist, 1965). This factor(s) present in bone 
matrix  was  named  bone  morphogenetic  protein  (BMP) 
(Urist,  1971). It was purified from demineralized bovine 
bone matrix (Wang et al., 1988;  Luyten et al., 1989;  Sam- 
path et al.,  1990),  and human cDNAs  Of eight different 
BMPs have been cloned (Wozney et al., 1988; Celeste et al., 
1990;  0zkaynak et al.,  1990, 1992).  The deduced amino 
acid sequences of BMPs have indicated that BMP-2 through 
BMP-8 are members of the TGF-~ superfamily (Wozney et 
al., 1988; Celeste et al., 1990; Ozkaynak et al., 1990, 1992), 
which is an important regulator of the differentiation  of vari- 
ous types of Cells and organs (for review see Roberts and 
Sporn,  1990). 
Recently, we reported that recombinant human BMP-2 
stimulates osteoblastic maturation in osteoblast progenitor 
cells, ROB-C26, and induces the pluripotent fibroblastic cell 
line, C3H10TI/2,  to differentiate into osteoblast-like cells 
(Katagiri et al.,  1990a;  Yamaguchi  et al.,  1991). These 
results suggest that BMP-2 not only stimulates the matura- 
tion of committed osteoblast progenitors, but also induces 
the commitment  of  undifferentiated  non-osteogenic cells into 
osteoblasts. We also reported that BMP-2 inhibited myotube 
formation in  ROB-C26  cells  and  L-6 myoblasts in  vitro 
(Yarnaguchi et al., 1991). These results led us to examine the 
possibility that BMP-2 regulates the differentiation pathway 
of myogenic cells around the sites of BMP-2 implantation. 
We report here that BMP-2 inhibits myotube formation of 
myoblastic C2C12  cells by suppressing myogenin mRNA 
and inducing IdA  mRNA expression.  More importantly, 
BMP-2 converts the differentiation pathway of C2C12 cells 
into that of osteoblast lineage. 
Materials and Methods 
Bone Morphogenetic Protein-2 and Transforming 
Growth Factor-~  l 
Bioactive recombinant human BMP-2 (BMP-2) was produced and purified 
from the conditioned medium of CHO cells as described previously (Wang 
et al.,  1990).  The purity of the protein was over 90% as judged by silver 
staining  on  SDS-polyacrylamide  gels  and  amino-terminal  sequencing. 
Recombinant human TGF-/~I  was purchased from R &  D  Systems, Inc. 
(Minneapolis, MN). 
Cell Culture 
The mouse myoblast cell line, C2C12  (Blau  et al.,  1983),  was purchased 
from the Amer. Type Culture Collection. C2C12  cells were maintained in 
DMEM (Sigma Chem. Co., St. Louis, MO) containing 15 % FBS (GIBCO, 
Grand Island, NY) and antibiotics (100 U/ml of Penicillin-G and 100 #g/ml 
of Streptomycin) (growth medium) at 37°C in a humidified atmosphere of 
5% CO2 in air. Primary muscle cells were prepared from thigh muscles of 
1-d-old mice (ddY strain) as described previously (Yaffe, 1973).  The cells 
were inoculated at 2  ×  104 cells/cm  2 and cultured with growth medium. 
To examine the effects of BMP-2 and TGF-/31 on muscle and osteoblast 
differentiation in C2C12 ceils and primary muscle cells, the growth medium 
was replaced on day  1 and  DMEM  containing 5%  FBS  (low  mitogen 
medium) with various concentrations of these growth factors. 
Histochemical  Analyses 
To examine alkaline phosphatase activity histochemically, ceils were fixed 
for 10 rain with 3.7%  formaldehyde at room temperature. After washing 
with PBS, the cells were incubated for 20 min with a mixture of 0.1 mg/ml 
of  naphthol AS-MX phosphate (Sigma Chem. Co.), 0.5 % N,N-dimethylfor- 
mamide, 2 mM MgC12, and 0.6 mg/ml of fast blue BB salt (Sigma Chem. 
Co.) in 0.1 M Tris-HC1,  pH 8.5,  at room temperature. 
To analyze expression of troponin T  (Tn T)  and myosin heavy chain 
(MHC) immunohistochemically, the cells were fixed for 10 rain at room 
temperature with 3.7%  formaldehyde. They were washed with PBS and 
treated for 1 rain with an acetone/ethanol mixture (50:50, vol/vol) at -200C 
to permeate the cell membrane. After incubating the cells for 10 min with 
10%  normal rabbit serum to block non-specific binding, they were in- 
cubated for 1 h with mouse anti-Tn T monoclonal antibody (NT-30'2; pro- 
vided by Dr. T. Obinata, Chiba University, Japan) (Abe et al.,  1986) or 
mouse anti-MHC monoclonal antibody (MF-20; purchased from Develop- 
mental Studies Hybridoma Bank, Iowa City, IA) (Bnder et al.,  1982)  at 
room temperature. The cells were washed with PBS, and then incubated for 
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globulins).  The  cells  were washed with  PBS,  and then incubated with 
peroxidase-conjugated streptavidin. The reaction products were visualized 
using an AEC substrate kit (Histofine, Niehirei Co., Tokyo, Japan). Occa- 
sionally, the Tn T-positive myotubes were counted in 11.6 mm  2 at arbitrar- 
ily selected area of each culture after immunohistochemical staining. 
Colony Formation Assay 
After C2C12 cells were cultured for 6 d with or without 300 ng/ml of  BMP-2 
as described above, they were replated at 500 cells/well in 6-well plates and 
maintained for 9  d  in DMEM containing 15%  FBS with or without 300 
ng/ml of BMP-2. To stimulate myotube formation, the cells were incubated 
for additional 3 d in DMEM containing 5 % FBS in the presence or absence 
of 300 ng/ml of  BMP-2. The colonies formed were fixed and double stained 
for Tn T and ALP activity as described above. The colonies formed in each 
culture were divided into four groups by the expression pattern of Tn T 
immunoreactivity and ALP activity: "In T+/ALP-; colonies containing nu- 
merous Tn T-positive myotubes but no ALP-positive cells, Tn T-/ALP+; 
colonies containing numerous ALP-positive cells but no Tn T-positive cells, 
Tn  T+/ALP+;  colonies containing both Tn  T-positive and  ALP-positive 
cells at various proportions, and Tn T-/ALP-; colonies containing neither 
"In T-positive cells nor ALP-positive cells. 
Alkaline Phosphatase Activity 
After removing the culture medium, cell layers were washed with PBS, and 
then sonicated for 10 s at 0*C three times in 50 mM Tris-HC1,  0.1% Triton 
X-100, pH 7.5. ALP activity in the cell lysate was assayed at 37"C in the 
buffer containing 0.1  M  2-amino-2-methyl-l-propunol and 2  mM MgCI2, 
pH 10.5, for 30 min using p-nitrophenylphosphate as a substrate. The en- 
zyme activity was expressed as mieromoles ofp-nitrophenol produced per 
rain per nag of protein. The protein content was determined using the BCA 
protein assay kit (Pierce Chemical Co.,  Rockford, IL) using BSA as the 
standard. 
Osteocalcin Production 
The amount of  osteocalcin secreted into the culture medium was determined 
by RIA using a mouse osteocalcin assay kit (Biomedical Technologies Inc., 
Stoughton, MA). 
3',5'-cAMP Production in Response to PTH 
To measure responsiveness to PTH, the amount of cAMP produced by the 
cells was assayed. Ceils were cultured for 20 rain at 37°C with DMEM con- 
raining 0.5% BSA and 1 mM 3-isobuthyl-l-methylxanthine. Thereafter, the 
cells were incubated for 10 min at 37°C with 200 ng/ml of  human PTH(1-34) 
(provided by Dr. M. Hori, Asahi-Kasei Co., Shizuoka, Japan) dissolved in 
the same media. The cAMP produced by the cells was extracted with etha- 
nol containing 3 mM HCI at 4°(2 for 2 h. The extract was dried by boiling, 
and dissolved in 3 mM HC1. The content of cAMP was determined using 
a cAMP RIA kit (Yamasa  Co., Chiba, Japan). 
RNA Preparation  and Northern Blots 
Total  cellular RNA was extracted from C2C12 cells according to an acid 
guanidium thiocyanate-phenol-ehloroform  method (Chomezynski and Sac- 
chi,  1987).  Ten or twenty micrograms of total RNA was electrophoresed 
in 1.2 % agarose-formaldehyde gels, and transferred onto Hybond-N mem- 
branes (Amersham International, Amersharn, UK). The membranes were 
prehybridized  for 3 h at 42°C in 50% formamide; 5  x  SSC; 5 ×  Denhardt's 
solution; 50 mM Tris-HC1,  pH 7.5; 0.1% SDS; and 250 ~g/ml of salmon 
sperm DNA. Thereafter, the membranes were hybridized with 32p-labeled 
eDNA probes overnight at 42°C. The labeled probes were prepared using 
a  DNA  random priming kit  (Takara  Shuzo Co.,  Kyoto, Japan)  and  [,- 
Figure 1.  The effects of BMP-2 on induction of Tn T  and ALP activity in C2C12  cells. The cells were cultured for 6  d  with (b and d) 
or without (a and c) 300 ng/ml of BMP-2 as described in Materials and Methods. The cultured cells were fixed and stained for Tn T 
(a and b) and ALP (c and d)  as described in Materials and Methods. Bars,  100 #m. 
Katagiri  et al. Osteoblast Differentiation of Myoblasts  1757 32p]dCTP (New England Nuclear, Boston, MA). The membranes were 
washed three times at room temperature in 2 x SSC containing 0.1% SDS 
and twice  at 55°C in 0.1 x SSC containing 0.1% SDS and autoradiographed 
at -80°C. Sometimes,  the hybridized probes  were removed  from  the mem- 
branes by boiling them in 0.5% SDS, and rehybridized. The eDNA  probes 
were those for the rat ALP (Noda et al., 1987), rat PTH/PTHrP  receptors 
(Jiippner et al., 1991), rat osteocalcin (Celeste et al., 1986), mouse MCK, 
mouse MyoD  (Davis  et al., 1987), mouse  myogenin  (Fujisawa-Sehara  et al., 
1990), mouse Id-1 (Hara et al.,  1994), and mouse glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH). 
Results 
Effects of  BMP-2 on the Muscle and 
Osteoblast Differentiation 
C2C12 cells generated numerous multinucleated myotubes 
on day 6, when they were cultured in low mitogen medium. 
The myotubes formed were positive for both Tn T (Fig.  1 a) 
and MHC (data not shown) by immunohistochemical stain- 
ing. An enzyme histochemical study showed that these cells 
were negative for ALP  (Fig.  1 c).  BMP-2  exposure (300 
ng/ml) for 6 d inhibited the formation of multinucleated myo- 
tubes (Fig. 1 b). The cells remained as unfused mononuclear 
polygonal cells  in  the  presence  of BMP-2.  These  mono- 
nuclear cells were negative for both Tn T (Fig. 1 b) and MHC 
(data not shown).  Incubation with BMP-2 (300 ng/ml) for 
6 d  strikingly induced ALP-positive cells (Fig.  1 d).  Over 
90% of the mononuclear cells were ALP positive (Fig. 1 d). 
A few multinucleated myotubes that formed in the presence 
of BMP-2 were negative for ALP. 
Fig.  2  shows  the  dose-dependent  effects of BMP-2  on 
differentiation of C2C12 cells cultured for 6 d in low mitogen 
medium. Incubating C2C12 cells with BMP-2 dose depen- 
dently decreased the number of myotubes, which slightly de- 
creased at 100 ng/ml and almost completely disappeared at 
concentrations above 300 ng/rnl of BMP-2 (Fig. 2 a). C2C12 
cells cultured without BMP-2 expressed extremely low or 
undetectable levels of osteoblastic phenotypes such as ALP 
activity,  PTH responsiveness,  and  osteocalcin production 
(Fig. 2). ALP activity was slightly induced at 100 ng/ml and 
markedly increased at more than 300 ng/ml of BMP-2 (Fig. 
2 b). BMP-2 at concentrations of more than 300 ng/ml in- 
duced high levels of cAMP in response to PTH; an 8.1-fold 
increase at 300 ng/ml and a 13.6-fold increase at 1,000 ng/ml 
(Fig. 2 c). BMP-2 slightly induced osteocaicin production at 
100 ng/ml and markedly induced it at concentrations above 
300 ng/ml (Fig. 2 d). The concentration of BMP-2 required 
to induce osteoblastic phenotypes was almost identical to 
that required to inhibit myotube formation (Fig.  2). 
A time course study in the control culture with low mito- 
gen medium showed that myotubes first appeared on day 3 
and that the number increased time dependently until day 6 
(Fig. 3 a). However, 300 ng/ml of BMP-2 almost completely 
abolished myotube formation in C2C12 ceils during the en- 
tire culture period (Fig. 3 a). When C2C12 cells were cul- 
tured in the presence of 300 ng/ml of BMP-2, both ALP ac- 
tivity and  osteocalcin production  began to  appear within 
48 h, and then increased time dependently until day 6 (Fig. 
3, b and c). 
The effects of BMP-2 were reproducible in primary muscle 
cells isolated from thigh muscles of 1-d-old  mice as well. 
When  primary muscle cells were treated with BMP-2  for 
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Figure 2. Dose-response effects of BMP-2 on myotube formation, 
ALP activity, PTH-dependent cAMP accumulation, and osteocal- 
cin production in C2C12 cells. The cells were cultured for 6 d with 
graded  concentrations  of BMP-2 as described  in  Materials  and 
Methods. (a) The number of myotubes was counted after staining 
for Tn T as described in Materials and Methods. (b) The ALP activ- 
ity of the cell lysate was measured using p-nitrophenylphosphate as 
a substrate. (c) The amounts of cAMP accumulation in response to 
PTH were  measured  by RIA.  (d)  The  amounts  of osteocalcin 
secreted into the culture media were determined by RIA. Data are 
means  -F SEM of three wells. 
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Figure 3. Time course of changes in myotube formation, ALP activ- 
ity, and osteocalcin production in C2C12 cells. Cells were cultured 
with (e) or without  (o) 300  ng/ml of BMP-2 for the  indicated 
times. (a) The number of myotubes was counted after staining for 
Tn T as described in Materials and Methods. (b) The ALP activity 
of the cell lysate was measured using p-nitrophenylphosphate  as a 
substrate. (c) The amounts of osteocalcin secreted into the culture 
media were determined by RIA. Data are means  +  SEM of three 
wells. 
6 d,  the  number of myotubes was  decreased dose depen- 
dently (Fig. 4 a). At 300 ng/ml or higher of BMP-2, myo- 
tubes  disappeared almost completely (Fig.  4  a).  Primary 
muscle ceils cultured without BMP-2 expressed essentially 
no osteoblastic phenotype, but the cells exposed to BMP-2 
at concentrations higher than 300 ng/ml expressed high lev- 
els of ALP activity and osteocalcin production (Fig. 4, b and 
c). The effective dose levels of BMP-2 to inhibit myogenic 
phenotype and to induce osteoblast phenotype were almost 
identical between primary muscle ceils and C2C12 cells. 
To determine whether BMP-2 expresses osteoblast pheno- 
types at the transcriptional level, mRNA expression for myo- 
genic and osteoblast differentiation was examined by North- 
ern  blotting.  When  C2C12  ceils  were  cultured  with  low 
mitogen medium, they expressed MCK mRNA at 48 h and 
the expression increased in a time-dependent manner (Fig. 
5, MCK, lane A). BMP-2 at 300 ng/ml diminished the ex- 
0  1  3  10  30  100  300  1000 
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Figure 4. Dose-response effects of BMP-2 on myotube formation, 
ALP activity, and osteocalcin production in primary muscle ceils. 
The cells  were  cultured  for 6 d  with  graded  concentrations  of 
BMP-2 as described in Materials and Methods. (a) The number of 
myotubes was counted  after staining  for Tn T  as  described  in 
Materials and Methods. (b) The ALP activity of the cell lysate was 
measured  using p-nitrophenylphosphate  as  a  substrate.  (c)  The 
amounts of osteocalcin secreted into the culture media were deter- 
mined by ILIA. Data are means  +  SEM of three wells. 
pression of MCK mRNA almost completely (Fig. 5, MCK, 
lane B).  The untreated  C2C12  cells  did  not  express  any 
mRNAs for ALP, PTH/PTHrP receptors, and osteocalcin 
during the entire culture period.  BMP-2  at 300  ng/ml in- 
duced the expression of ALP and osteocalcin mRNAs within 
48 h  (Fig.  5,  ALP and osteocalcin,  lane B).  BMP-2  (300 
ng/ml) also induced  a  weak but detectable level of PTH/ 
PTHrP receptors mRNA within 48 h (data not shown). The 
expressed levels of mRNAs of these osteoblast phenotypes 
increased in a time-dependent manner. 
Effects of  BMP-2 on mRNA Expression 
of  HLH Proteins 
To investigate the mechanism of the inhibitory effect on the 
myogenic differentiation of BMP-2, the mRNA expression of 
HLH proteins such as myogenin, MyoD, and Id-1 was exam- 
Katagiri et al. Osteoblast Differentiation of Myoblasts  1759 Figure 5. Northern blots of the expression of phenotypes of myo- 
genic and osteoblast differentiation in C2C12 cells. Cells were cul- 
tured  with or without BMP-2 (300 ng/ml) or TGF-BI  (5 ng/ml) 
for the indicated periods. Total RNA from each culture (20 #g) was 
separated in a formaldehyde-agarose gel and sequentially hybrid- 
ized with the respective eDNA probes as described in Materials and 
Methods. A, control culture;  B, BMP-2-treated  culture;  C, TGF- 
B  1-treated culture. 
Figure 6. Expression of  the mRNA of  HLH proteins which regulate 
myogenic differentiation in C2C12 cells. The cells were cultured in 
the presence or absence of  BMP-2 (300 ng/ml) or TGF-/~  1 (5 ng/ml) 
for the indicated periods.  Total RNA prepared  from each culture 
(10 #g) was separated in a formaldehyde-agarose gel and sequen- 
tially hybridized with the respective eDNA probes as described in 
Materials and Methods. A, control culture; B, BMP-2-treated cul- 
ture;  C, TGF-/~l-treated culture. 
ined.  These proteins are important regulators of myogenic 
differentiation.  C2C12  cells cultured  with growth medium 
expressed substantial levels of mRNA for MyoD and Id-1, 
but  none  for  that  of myogenin  (Fig.  6,  0  h).  When  the 
medium was changed from growth to low mitogen medium 
in the absence of BMP-2,  myogenin mRNA was expressed 
at 24 h and it increased thereafter. In contrast, Id-1 mRNA 
was downregulated within 3 h  (Fig.  6).  The expression of 
MyoD mRNA was stimulated within 24 h in the control cul- 
ture  (Fig.  6).  BMP-2  (300  ng/ml)  almost completely in- 
hibited  the  increase  in  myogenin  mRNA  expression  in 
C2C12  cells.  The  expression  of MyoD  mRNA  was  tran- 
siently  stimulated  at  1-3  h  but  decreased  thereafter  by 
BMP-2.  BMP-2  also  increased  the  level  of Id-1  mRNA 
within 1 h, but decreased it gradually thereafter. The expres- 
sion profile of Id-1 mRNA induced by BMP-2 was identical 
to that of MyoD.  The expression level of Id-1  was always 
higher  in  BMP-2-treated  cells  than  in  the  corresponding 
control cells. 
The Fate of  the Phenotype of  the Colonies Formed  from 
C2C12 Cells Pretreated with or without BMP-2 
To determine whether the effects of BMP-2 on the muscle 
and ostcoblastic differentiation are heritable, the colony for- 
mation  assay  was  performed  by  replating  C2C12  cells 
pretreated for 6 d with or without 300 ng/ml of BMP-2. The 
colonies were maintained for 12 d in the presence or absence 
of 300 ng/ml of BMP-2. The colonies formed in each culture 
were divided into four groups (Tn T+/ALP  -, Tn T-/ALP  +, 
Tn T+/ALP  +, and Tn T-/ALP-) by the expression pattern of 
Tn T immunoreactivity and ALP activity. The phenotype of 
the colonies depended on the presence or absence of BMP-2 
in the colony assay but not in the pretreatment culture (Fig. 
7  and  Table I).  Almost  all  (over  83.9%)  of the  colonies 
formed from C2C12 cells pretreated with or without BMP-2 
were Tn T+/ALP  ,  when they were maintained in the ab- 
sence of BMP-2  in the  colony assay.  However, more than 
84%  of  the  colonies  became  Tn  T-/ALP  +  by  culturing 
C2C12 cells with BMP-2 in the colony assay, irrespective of 
the presence or absence of BMP-2 in the pretreatment cul- 
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and osteoblastic  properties  in the colony 
formation assay. C2C12 cells cultured for 
6 d with (e-h) or without (a-d) 300 ng/ml 
of BMP-2 were replated at 500 cells/weU in 
6-well  plates  and maintained for  9  d  in 
DMEM containing 15 % FBS in the pres- 
ence (c, d, g, and h) or absence (a, b, e, and 
f)  of 300 ng/ml of BMP-2.  To stimulate 
myombe formation, the colonies were  in- 
cubated for 3 additional d in DMEM con- 
taining  5 % FBS in the presence (c, d, g, and 
h) or absence (a, b, e, and  f) of 300 ng/ml 
of  BMP-2.  The  colonies  were  double- 
stained for Tn T expression and ALP activ- 
ity as described in Materials and Methods. 
The right panels (b, d, f, and h) show the 
typical colonies corresponding to each well 
in the left panels (a, c, e, and g), respec- 
tively. Bars,  1 mm. 
Katagiri et al. Osteoblast  Differentiation of Myoblasts  1761 Table L  The Fate of the Phenotype of the Colonies Formed from C2C12  Cells Pretreated with or without BMP-2 
Presence or absence 
Pretreatment  of BMP-2 in the 
with BMP-2  colony assay 
for 6 d  (on day  12) 
Phenotype of colonies 
Tn T+/ALP  -  Tn T-/ALP  +  Tn T+/ALP  +  Tn T-/ALP- 
Number of  colonies/well  (% of  total  colonies)  Total 
-  93  (88.5)  1 (1.0)*  0  (0.0)  11  (10.5)  105 
+  0  (0.0)  82 (93.2)  2  (2.3)*  4  (4.5)  88 
-  73  (83.9)  0  (0.0)  2  (4.6)~  10 (11.5)  87 
+  7 (1.2)*  85  72 (84.7)  4 (4.7)*  8 (9.4) 
The colony assay was performed by the method described in Materials and Methods using C2C12 cells pretreated for 6 d with or without 300 ng/ml of BMP-2. 
The colonies were divided into four groups by the expression pattern of ALP activity and Tn T immunoreactivity. The number of colonies was counted as described 
in Materials and Methods. Data are expressed as the number of colonies in a well. The data in the parentheses are the percentages of the colonies to total colonies. 
* The colonies consisted of a small number of ALP-positive or "In T-positive cells. 
* The colonies consisted of a large number of ALP-positive cells and a small number of Tn T-positive cells. 
§ The colonies consisted of a large number of "In T-positive cells and a small number of ALP-positive cells. 
ture. A small number of the colonies formed in each culture 
were Tn T-/ALP- (',,11.5%) or Tn T+/ALP  + (~4.7%) (Ta- 
ble I).  The proportion of these colonies to total colonies 
were similar between the four groups. 
Effects of TGF-[31 on Muscle and 
Osteoblast Differentiation 
Like BMP-2,  treatment with TGF-~I for 6 d  partially re- 
duced the number of myotubes of 0.5 ng/ml and almost com- 
pletely inhibited its formation at 5 ng/ml in C2C12 cells (Fig. 
8 a). TGF-~I markedly suppressed the expression of myoge- 
nin and MyoD mRNAs without the transient stimulation of 
Id-1 mRNA (Fig. 6). TGF-/31 (0.5 and 5 ng/ml) did not in- 
duce ALP activity, osteocalcin production (Fig. 8, b and c), 
or the mRNA for these proteins (Fig. 5, lane C). When 0.5 
ng/ml of TGF-~ was added to the culture in the presence of 
100 ng/ml of BMP-2, it potentiated the inhibitory effect of 
BMP-2 on myotube formation in C2C12 cells (Fig. 8 a). In 
contrast, TGF-ffl inhibited ALP activity at 5 ng/ml and os- 
teocalcin production at 0.5 ng/ml, both induced by 300 ng/ml 
of BMP-2 (Fig.  8, b and c). 
Discussion 
This study demonstrated that BMP-2 not only inhibits the 
myogenic differentiation of C2C12 myoblasts but also con- 
verts  their  differentiation pathway  into  that  of osteoblast 
lineage. The C2C12 cells differentiated into multinucleated 
myotubes when  the  concentration of FBS  in  the  culture 
medium was reduced from 15 to 5 %. Under the culture con- 
dition for myogenic differentiation, 300 ng/ml of BMP-2 al- 
most completely inhibited the formation of myotubes which 
expressed  Tn  T  and  MHC.  Under  the  same  conditions, 
BMP-2 induced the expression of typical osteoblast pheno- 
types such as ALP activity, cAMP production in response to 
PTH, and osteocalcin production in C2C12 cells. Reduction 
of the FBS concentration in the medium was required for in- 
ducing myogenic differentiation in C2C12 cells, but not for 
osteoblast  differentiation by  BMP-2,  since  ALP-positive 
cells were similarly induced in the presence of 15 % FBS (un- 
published observation). These results clearly indicate that 
the C2C12 myoblasts treated with BMP-2 converted the dif- 
ferentiation pathway into that of osteoblast lineage. Similar 
effects of BMP-2 were recognized in primary muscle cells 
isolated from thigh muscles of 1-d-old  mice as well.  It is 
therefore likely that the in vitro culture system using C2C12 
myoblasts provides a useful experimental model for inves- 
tigating the mechanism of ectopic bone formation induced 
by implanting BMP into muscular tissues. 
When C2C12 cells were incubated for 6 d with 300 ng/ml 
of BMP-2,  over 90%  of the cells expressed ALP activity 
without Tn T expression. However, when they were further 
maintained for 12 d in the absence of BMP-2, almost all of 
the colonies expressed Tn T  but not ALP activity. These 
results indicate that C2C12 cells which had been induced to 
differentiate into osteoblastic lineage cells by BMP-2 are 
capable of differentiating into mature  muscle cells  again 
when BMP-2 is removed. Furthermore, a large number of 
ALP-positive colonies appeared when they were maintained 
with BMP-2. These results indicate that BMP-2 is necessary 
not only for inhibiting  terminal  differentiation of muscle 
cells  and  inducing osteoblast differentiation, but also  for 
maintaining the differentiation pathway converted to the os- 
teoblast lineage. It was also suggested that the conversion of 
the differentiation pathway caused by BMP-2 was not herita- 
ble. The relevance of these findings to development as well 
as the mechanism of regulation of muscle and osteoblast 
differentiation by  BMP-2,  however,  need  further investi- 
gation. 
C2C12 is a subclone isolated from parental C2 myoblasts, 
which were established from the regenerating thigh muscle 
of an adult mouse (Blau et al., 1983; Yaffe and Saxel, 1977). 
The cells are thought to be derived from satellite cells, which 
are mononucleated cells lying along the muscle fibers in the 
normal tissue, and exist throughout the adult life as a poten- 
tial source of new myoblasts. When muscular tissues receive 
injury or some dystrophic stimuli, the satellite cells divide 
and differentiate into myoblasts and fuse to form muscle 
fibers (for review see Stockdale, 1992). In our preliminary 
experiments using parental C2 cells, BMP-2 also inhibited 
myotube formation and induced ALP activity and osteocal- 
cin production. These characteristics of C2C12 and C2 cells 
indicate  that  the  satellite  cells  are  potential  progenitors 
differentiating into osteoblasts in response to BMP-2 during 
ectopic bone formation at muscular tissues. 
This study showed that the expression of MyoD mRNA 
was reduced in C2C12 cells incubated with BMP-2 for more 
than 24 h. Furthermore, no expression of myogenin mRNA 
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Figure 8. Effects of combination treatment of BMP-2 and TGF-/31 
on myotube formation, ALP activity, and osteocalcin production in 
C2C12 cells. The cells were cultured for 6 d with or without BMP:2 
(0, 100, 300 ng/ml) and/or TGF-/31 (0, 0.5, 5 ng/ml) as described 
in  Materials  and  Methods.  (a)  The number  of myotubes was 
counted after staining for Tn T  as described  in  Materials  and 
Methods. (b) The ALP activity of the cell lysate was measured 
using p-nitmphenylphosphate as a substrate. (c) The amounts of  os- 
teocalcin secreted into the culture media were determined by RIA. 
Data are means  +  SEM of three wells. 
was  induced  by  BMP-2.  Several  lines  of evidence  have 
demonstrated that among various myogenic factors, myoge- 
nin plays an  important role in  terminal  differentiation of 
committed myoblasts into mature muscle ceils. Adding an 
antisense oligonucleotide for myogenin blocked the  myo- 
genic  differentiation of myoblasts  in  vitro  (Brunetti  and 
Goldfine,  1990).  Furthermore, skeletal muscles developed 
abnormally in the myogenin knockout mouse (Hasty et al., 
1993; Nabeshima et al.,  1993). Although mice lacking ei- 
ther the MyoD or the Myf-5 gene developed well with nor- 
mal skeletal muscles, it has been suggested that MyoD and 
Myf-5 share a  redundant function required for generating 
the muscle cell identity and activating myogenin (Braun et 
al.,  1992; Rudnicki et al.,  1992,  1993). We demonstrated 
that BMP-2 transiently stimulated the expression of MyoD 
mRNA within 3 h. In a time course experiment, the change 
of expression levels of MyoD was almost identical to that of 
IdA  in the cells incubated with BMP-2.  Jen et al.  (1992) 
reported that overexpression of Id-1 in C2C12 cells inhibited 
myogenesis by binding to E12/E47 and preventing the forma- 
tion of heterodimers between E12/E47 and myogenic HLH 
proteins. These suggest that the activity of MyoD transiently 
stimulated by BMP-2 is blocked by Id-1, which is concur- 
rently induced by BMP-2. Consequently, C2C12 ceils treated 
with BMP-2 might fail to express myogenin. The cooperative 
regulation in mRNA expression between the positive (myo- 
genin) and the negative regulators (ld-1) induced by BMP-2 
may play, at least in part, an important role in inhibiting myo- 
genic differentiation. 
Myogenic differentiation is also inhibited by other growth 
factors such as TGF-/3 and basic FGF (bFGF) (Massagu6 et 
al.,  1986;  Spizz et al.,  1986,  1987;  Florini et al.,  1986; 
Clegg  et  al.,  1987;  Vaidya  et  al.,  1989;  Brunetti  and 
Goldfine, 1990; Brennan et al.,  1991; Martin et al.,  1992; 
Hardy et al., 1993). These growth factors inhibit the expres- 
sion of MyoD and myogenin mRNAs (Vaidya et al.,  1989; 
Brunetti and Goldfine, 1990). In addition, bFGF induces the 
phosphorylation by protein kinase C at a conserved site of 
the DNA-binding domain of myogenin, which causes a loss 
of DNA-binding activity of  myogenin (Li et al., 1992). It has 
also been reported that TGF-/3 inhibits the activity of myo- 
genic  factors  through  a  mechanism  independent of both 
DNA-binding and Id-1 induction (Brennan et al., 1991). Like 
these growth factors, BMP-2 completely inhibited expres- 
sion of  myogenin in C2C12 cells. Contrary to TGF-/3, BMP-2 
induced a transient stimulation of expression levels of Id-1 
mRNA in C2C12 cells. When C2C12 cells were incubated 
with a suboptimal dose of BMP-2 and TGF-/31, myotube for- 
marion was  inhibited more strikingly than the cells were 
treated with either factor. These results suggest that BMP-2 
inhibits myogenic differentiation through a different mecha- 
nism from that of bFGF and TGF-/3. BMP-2 may change the 
DNA binding and/or transcriptional activities of MyoD in 
C2C12 cells. 
Recently,  Murray  et  al.  0993)  reported  that  partially 
purified BMP from demineralized bone inhibited myogenic 
differentiation in C2C12 and L6 myoblasts. They showed that 
the BMP fraction suppressed the mRNA expression of myo- 
genic factors after incubation for 1-2 wk, but there was no 
induction of osteoblast and chondroblast differentiation in 
these cells (Murray et al., 1993). The cause of the failure to 
induce osteoblast differentiation in their study is unknown. 
It may be due to the purity of the BMP (recombinant vs 
native). 
Since BMP-2 is a member of  the TGF-/3 superfamily, it was 
important to compare the effects of BMP-2 and TGF-ffl on 
osteoblast differentiation in  C2C12  cells.  BMP-2  induced 
C2C12  cells to differentiate into osteoblast-like cells,  but 
TGF-/31 did not. These results are consistent with our previ- 
ous experiments in which osteoblast differentiation of non- 
osteogenic C3H10T1/2 fibroblasts and osteoblast progenitor 
ROB-C26 cells was induced by BMP-2 but not by TGF-/31 
(Katagiri et al.,  1990a; Yamaguchi et al.,  1991).  Further- 
more, TGF-/31 reduced ALP activity and osteocalcin produc- 
tion induced by BMP-2 in C2C12 cells. TGF-/31 even sup- 
pressed ALP activity and osteocalcin production in some 
osteoblast-like cells in vitro (Noda and Rodan, 1986; Elford 
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1990b). Although TGF-/3 induced new bone formation when 
injected at the periosteal region in rive (Noda and Camil- 
liere,  1989;  Joyce et al.,  1990),  it did not induce ectopic 
bone formation by implantation at a muscular site (Sampath 
et al., 1987). These results indicate that the effect of BMP-2 
on osteoblast differentiation  differ from that of TGF-/31. The 
differences in the effects between BMP-2 and TGF-/3 may be 
caused by differences in their receptors and signal transduc- 
don systems. 
Several investigators  have reported that Id-1 and/or E12 
mRNAs are expressed in osteoblast-like cells in vitro, and 
that Id-1 expression is downregulated during the maturation 
of osteoblasts  as  well as  the  differentiation  of myoblasts 
(Murray et al., 1992; Kawaguchi  et al.,  1992). In addition, 
transfection of an Id-I expression vector into osteoblast-like 
cells inhibited ALP activity (Murray et al., 1992). Since the 
IdA protein is a negative regulator for bHLH factors in myo- 
blasts, these results suggest that some novel HLH proteins 
are  involved  in  the  regulatory  mechanism  of  osteoblast 
differentiation.  In the present study,  however, treatment  of 
C2C12 cells with BMP-2 markedly induced the expression 
of osteoblast phenotypes with a concomitant, but transient 
increase in Id-1 mRNA expression compared with the con- 
trol culture.  The stimulation of IdA  mRNA by BMP-2 has 
also been reported in the osteoblastic cell line, MC3T3-E1, 
and in the pluripotent fibroblastic cell line, C3H101/2  (Ogata 
et al.,  1993).  In these cells, BMP-2 stimulated or induced 
the  expression  of osteoblast  phenotypes  (Katagiri  et  al., 
1990a; Takuwa et al.,  1991).  These results suggest that os- 
teoblast differentiation  shares  a common mechanism  with 
muscle  differentiation  in  some aspects,  but also  involves 
some other mechanisms from muscle differentiation.  To the 
understanding  of the conflicting regulatory mechanisms of 
osteoblast  differentiation,  identification  of  the  osteoblast 
regulatory factors induced by BMP-2 is an important project 
in bone cell biology. 
In  conclusion,  BMP-2  inhibits  myotube  formation,  in- 
duces IdA expression, and suppresses myogenin expression. 
Also, BMP-2 converts  the differentiation  pathway of C2C12 
myoblasts  into that of osteoblast lineage. These results indi- 
cate that BMP-2 is a potent regulator in determining the os- 
teoblast  differentiation  of not  only  pluripotent  immature 
mesenchymal cells, but also that of committed myoblasts. 
Osteoblast and muscle differentiations  may be contradictory 
pathways to each other. BMP-2 appears to have capacities to 
withdraw the committed myoblasts from the differentiation 
pathway into myogenic lineage cells and to induce them to 
differentiate  into the osteoblast lineage. 
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